Placebo News and Research

RSS

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.

8 Sep 2010

Methylphenidate facilitates recovery from drug addiction

A brain-scanning study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, conducted with collaborators from Stony Brook University, reveals that an oral dose of methylphenidate, commonly known as Ritalin, improves impaired brain function and enhances cognitive performance in people who are addicted to cocaine.

7 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold.

7 Sep 2010

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

7 Sep 2010

Psilocybin reduces anxiety, improves mood with advanced-stage cancer: Study

In the first human study of its kind to be published in more than 35 years, researchers found psilocybin, an hallucinogen which occurs naturally in "magic mushrooms," can safely improve the moods of patients with advanced-stage cancer and anxiety, according to an article published online today in the Archives of General Psychiatry.

7 Sep 2010

Iron supplements reduce risk of iron deficiency and anemia in children with marginally low birth weights

Giving iron supplements to children with marginally low birth weights (2000-2500 grams) dramatically reduces the risk of developing iron deficiency and anemia. This is shown by Umeå researcher Magnus Domellöf and associates in the coming edition of the pediatric scientific journal Pediatrics.

6 Sep 2010

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

6 Sep 2010

Behavioral management program for migraine sufferers boosts confidence to self-manage symptoms: Study

For severe migraine sufferers, psychological treatments build on the benefits of drug therapy, according to a new study by Elizabeth Seng and Dr. Kenneth Holroyd from Ohio University in the US.

3 Sep 2010

New study may change the way clinicians make treatment decisions for patients who smoke

A study led by researchers in the Oregon Health & Science University Smoking Cessation Center may change the way clinicians make treatment decisions for their patients who smoke.

3 Sep 2010

BAP releases new guidelines on treatments for sleep disorders

Insomnia and other sleep disorders are very common, yet are not generally well understood by doctors and other health care professionals. Now the British Association for Psychopharmacology (BAP) has released up-to-the-minute guidelines in the Journal of Psychopharmacology, published by SAGE, to guide psychiatrists and physicians caring for those with sleep problems.

3 Sep 2010

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.

2 Sep 2010

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

2 Sep 2010

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar (LTX-109) treatment of skin infections caused by Gram positive bacteria.

2 Sep 2010

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment.

2 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

Inhibitex completes INX-189 Phase1a trial for HCV

Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.

2 Sep 2010

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

2 Sep 2010

WPI researchers: Cranberry juice cocktail blocks strain of S. aureus

Expanding their scope of study on the mechanisms of bacterial infection, researchers at Worcester Polytechnic Institute have reported the surprise finding from a small clinical study that cranberry juice cocktail blocked a strain of Staphylococcus aureus (S. aureus) from beginning the process of infection.

2 Sep 2010

Placebo News and Research

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Methylphenidate facilitates recovery from drug addiction

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

Psilocybin reduces anxiety, improves mood with advanced-stage cancer: Study

Iron supplements reduce risk of iron deficiency and anemia in children with marginally low birth weights

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

Behavioral management program for migraine sufferers boosts confidence to self-manage symptoms: Study

New study may change the way clinicians make treatment decisions for patients who smoke

BAP releases new guidelines on treatments for sleep disorders

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Inhibitex completes INX-189 Phase1a trial for HCV

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

WPI researchers: Cranberry juice cocktail blocks strain of S. aureus

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News